atnahs pharma uk limited
atnahs pharma uk limited Company Information
Company Number
08789556
Website
www.atnahs.comRegistered Address
sovereign house miles gray road, basildon, essex, SS14 3FR
Industry
Wholesale of pharmaceutical goods
Manufacture of basic pharmaceutical products
Telephone
01268943700
Next Accounts Due
December 2024
Group Structure
View All
Shareholders
pharmanovia bidco limited 100%
atnahs pharma uk limited Estimated Valuation
Pomanda estimates the enterprise value of ATNAHS PHARMA UK LIMITED at £980.9m based on a Turnover of £352.8m and 2.78x industry multiple (adjusted for size and gross margin).
atnahs pharma uk limited Estimated Valuation
Pomanda estimates the enterprise value of ATNAHS PHARMA UK LIMITED at £2.3b based on an EBITDA of £143.6m and a 16.02x industry multiple (adjusted for size and gross margin).
atnahs pharma uk limited Estimated Valuation
Pomanda estimates the enterprise value of ATNAHS PHARMA UK LIMITED at £45.4m based on Net Assets of £21.2m and 2.14x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Atnahs Pharma Uk Limited AI Business Plan
In just minutes, we combine Pomanda’s company and industry data with cutting edge Artificial Intelligence to build a comprehensive 27 section business plan. You then have 60 days to tailor the information, decide which sections to include or exclude, and add your own branding logos, images and color scheme to create your perfect plan.
Atnahs Pharma Uk Limited Overview
Atnahs Pharma Uk Limited is a live company located in essex, SS14 3FR with a Companies House number of 08789556. It operates in the manufacture of basic pharmaceutical products sector, SIC Code 21100. Founded in November 2013, it's largest shareholder is pharmanovia bidco limited with a 100% stake. Atnahs Pharma Uk Limited is a established, mega sized company, Pomanda has estimated its turnover at £352.8m with rapid growth in recent years.
Upgrade for unlimited company reports & a free credit check
Atnahs Pharma Uk Limited Health Check
Pomanda's financial health check has awarded Atnahs Pharma Uk Limited a 5 rating. We use a traffic light system to show it exceeds the industry average on 7 measures and has 4 areas for improvement. Company Health Check FAQs
7 Strong
1 Regular
4 Weak
Size
annual sales of £352.8m, make it larger than the average company (£28m)
£352.8m - Atnahs Pharma Uk Limited
£28m - Industry AVG
Growth
3 year (CAGR) sales growth of 36%, show it is growing at a faster rate (4.8%)
36% - Atnahs Pharma Uk Limited
4.8% - Industry AVG
Production
with a gross margin of 67.4%, this company has a lower cost of product (31.1%)
67.4% - Atnahs Pharma Uk Limited
31.1% - Industry AVG
Profitability
an operating margin of 12.8% make it more profitable than the average company (5.2%)
12.8% - Atnahs Pharma Uk Limited
5.2% - Industry AVG
Employees
with 270 employees, this is above the industry average (89)
270 - Atnahs Pharma Uk Limited
89 - Industry AVG
Pay Structure
on an average salary of £74k, the company has a higher pay structure (£60.2k)
£74k - Atnahs Pharma Uk Limited
£60.2k - Industry AVG
Efficiency
resulting in sales per employee of £1.3m, this is more efficient (£434.2k)
£1.3m - Atnahs Pharma Uk Limited
£434.2k - Industry AVG
Debtor Days
it gets paid by customers after 75 days, this is later than average (60 days)
75 days - Atnahs Pharma Uk Limited
60 days - Industry AVG
Creditor Days
its suppliers are paid after 85 days, this is slower than average (37 days)
85 days - Atnahs Pharma Uk Limited
37 days - Industry AVG
Stock Days
it holds stock equivalent to 94 days, this is more than average (77 days)
94 days - Atnahs Pharma Uk Limited
77 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 12 weeks, this is average cash available to meet short term requirements (10 weeks)
12 weeks - Atnahs Pharma Uk Limited
10 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 97.4%, this is a higher level of debt than the average (51.6%)
97.4% - Atnahs Pharma Uk Limited
51.6% - Industry AVG
atnahs pharma uk limited Credit Report and Business Information
Atnahs Pharma Uk Limited Competitor Analysis
Perform a competitor analysis for atnahs pharma uk limited by selecting its closest rivals and benchmarking them against 12 key performance metrics.
atnahs pharma uk limited Ownership
ATNAHS PHARMA UK LIMITED group structure
Atnahs Pharma Uk Limited has 4 subsidiary companies.
Ultimate parent company
TRITON MANAGERS V LTD
#0131704
ATNAHS INTERNATIONAL HOLDINGS LTD
#0082865
2 parents
ATNAHS PHARMA UK LIMITED
08789556
4 subsidiaries
atnahs pharma uk limited directors
Atnahs Pharma Uk Limited currently has 5 directors. The longest serving directors include Mrs Neeshe Williams (Aug 2019) and Mr Amit Patel (Aug 2019).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mrs Neeshe Williams | United Kingdom | 43 years | Aug 2019 | - | Director |
| Mr Amit Patel | United Kingdom | 45 years | Aug 2019 | - | Director |
| Amit Patel | United Kingdom | 45 years | Aug 2019 | - | Director |
| Felipe Florez | Switzerland | 47 years | Jun 2021 | - | Director |
| Mr James Burt | United Kingdom | 49 years | Dec 2021 | - | Director |
ATNAHS PHARMA UK LIMITED financials
Atnahs Pharma Uk Limited's latest turnover from March 2023 is £352.8 million and the company has net assets of £21.2 million. According to their latest financial statements, Atnahs Pharma Uk Limited has 270 employees and maintains cash reserves of £39 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 352,806,000 | 244,783,000 | 226,084,000 | 140,673,000 | 118,092,000 | 107,033,000 | 51,846,000 | 38,790,000 | 10,854,000 | 1,755,000 |
| Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost Of Sales | 114,906,000 | 93,730,000 | 90,911,000 | 50,530,000 | 39,246,000 | 32,818,000 | 13,386,000 | 14,014,000 | 3,236,000 | 831,000 |
| Gross Profit | 237,900,000 | 151,053,000 | 135,173,000 | 90,143,000 | 78,846,000 | 74,215,000 | 38,460,000 | 24,776,000 | 7,618,000 | 924,000 |
| Admin Expenses | 192,782,000 | 146,559,000 | 119,815,000 | 79,444,000 | 59,918,000 | 45,758,000 | 21,189,000 | 17,277,000 | 6,046,000 | 1,391,000 |
| Operating Profit | 45,118,000 | 4,494,000 | 15,358,000 | 10,699,000 | 18,928,000 | 28,457,000 | 17,271,000 | 7,499,000 | 1,572,000 | -467,000 |
| Interest Payable | 48,343,000 | 4,435,000 | 26,853,000 | 15,213,000 | 8,685,000 | 8,370,000 | 3,799,000 | 3,426,000 | 881,000 | 196,000 |
| Interest Receivable | 150,000 | 30,000 | 4,676,000 | 978,000 | 8,000 | 38,000 | 55,000 | 24,000 | 0 | 4,000 |
| Pre-Tax Profit | -3,075,000 | 89,000 | -6,819,000 | -3,536,000 | 12,062,000 | 24,118,000 | 14,185,000 | 4,747,000 | 702,000 | -659,000 |
| Tax | -1,227,000 | -18,000 | -136,000 | 251,000 | -2,477,000 | -5,012,000 | -3,066,000 | -1,850,000 | -384,000 | 0 |
| Profit After Tax | -4,302,000 | 71,000 | -6,955,000 | -3,285,000 | 9,585,000 | 19,106,000 | 11,119,000 | 2,897,000 | 318,000 | -659,000 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Profit | -4,302,000 | 71,000 | -6,955,000 | -3,285,000 | 9,585,000 | 19,106,000 | 11,944,000 | 2,897,000 | 318,000 | -659,000 |
| Employee Costs | 19,989,000 | 15,280,000 | 8,830,000 | 8,631,000 | 6,121,000 | 4,522,000 | 3,239,000 | 1,892,000 | 1,445,000 | 0 |
| Number Of Employees | 270 | 209 | 139 | 84 | 55 | 33 | 23 | 12 | 5 | |
| EBITDA* | 143,587,000 | 99,197,000 | 101,064,000 | 59,560,000 | 59,383,000 | 62,201,000 | 29,399,000 | 19,808,000 | 5,203,000 | 70,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 17,656,000 | 15,326,000 | 12,663,000 | 9,187,000 | 1,483,000 | 463,000 | 269,000 | 154,000 | 52,000 | 0 |
| Intangible Assets | 615,420,000 | 398,679,000 | 480,779,000 | 449,326,000 | 120,266,000 | 142,387,000 | 62,949,000 | 39,180,000 | 45,447,000 | 17,569,000 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 202,000 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 633,076,000 | 414,005,000 | 493,442,000 | 458,513,000 | 121,749,000 | 142,850,000 | 63,420,000 | 39,334,000 | 45,499,000 | 17,569,000 |
| Stock & work in progress | 29,806,000 | 39,928,000 | 32,854,000 | 18,180,000 | 14,489,000 | 7,101,000 | 8,073,000 | 4,333,000 | 1,607,000 | 348,000 |
| Trade Debtors | 73,311,000 | 59,415,000 | 26,614,000 | 32,204,000 | 18,162,000 | 22,903,000 | 12,566,000 | 6,289,000 | 2,308,000 | 856,000 |
| Group Debtors | 0 | 1,156,000 | 8,080,000 | 0 | 893,000 | 0 | 0 | 0 | 0 | 540,000 |
| Misc Debtors | 28,146,000 | 10,189,000 | 29,030,000 | 71,508,000 | 10,010,000 | 876,000 | 1,280,000 | 1,538,000 | 1,262,000 | 907,000 |
| Cash | 39,035,000 | 42,673,000 | 16,637,000 | 15,525,000 | 2,528,000 | 1,213,000 | 2,907,000 | 15,891,000 | 3,287,000 | 212,000 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 170,298,000 | 153,361,000 | 113,215,000 | 137,417,000 | 46,082,000 | 32,093,000 | 24,826,000 | 28,051,000 | 8,464,000 | 2,863,000 |
| total assets | 803,374,000 | 567,366,000 | 606,657,000 | 595,930,000 | 167,831,000 | 174,943,000 | 88,246,000 | 67,385,000 | 53,963,000 | 20,432,000 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 29,352,000 | 16,573,000 | 0 | 0 | 0 | 0 |
| Trade Creditors | 27,040,000 | 10,649,000 | 10,357,000 | 59,553,000 | 5,484,000 | 1,867,000 | 2,894,000 | 2,662,000 | 892,000 | 308,000 |
| Group/Directors Accounts | 33,243,000 | 0 | 0 | 0 | 0 | 376,000 | 683,000 | 56,087,000 | 51,773,000 | 20,093,000 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 16,717,000 | 0 | 1,764,000 | 0 | 0 |
| hp & lease commitments | 427,000 | 360,000 | 253,000 | 172,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 106,336,000 | 36,312,000 | 45,936,000 | 16,987,000 | 11,328,000 | 9,185,000 | 2,164,000 | 3,693,000 | 1,639,000 | 690,000 |
| total current liabilities | 167,046,000 | 47,321,000 | 56,546,000 | 76,712,000 | 46,164,000 | 44,718,000 | 5,741,000 | 64,206,000 | 54,304,000 | 21,091,000 |
| loans | 495,597,000 | 481,596,000 | 989,418,000 | 924,328,000 | 79,775,000 | 97,918,000 | 67,857,000 | 0 | 0 | 0 |
| hp & lease commitments | 3,592,000 | 3,924,000 | 4,038,000 | 4,066,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 123,142,000 | 16,679,000 | 27,488,000 | 20,121,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 615,147,000 | 494,351,000 | 522,197,000 | 482,285,000 | 79,775,000 | 97,918,000 | 67,857,000 | 0 | 0 | 0 |
| total liabilities | 782,193,000 | 541,672,000 | 578,743,000 | 558,997,000 | 125,939,000 | 142,636,000 | 73,598,000 | 64,206,000 | 54,304,000 | 21,091,000 |
| net assets | 21,181,000 | 25,694,000 | 27,914,000 | 36,933,000 | 41,892,000 | 32,307,000 | 14,648,000 | 2,556,000 | -341,000 | -659,000 |
| total shareholders funds | 21,181,000 | 25,694,000 | 27,914,000 | 36,933,000 | 41,892,000 | 32,307,000 | 14,648,000 | 2,556,000 | -341,000 | -659,000 |
| Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||
| Operating Profit | 45,118,000 | 4,494,000 | 15,358,000 | 10,699,000 | 18,928,000 | 28,457,000 | 17,271,000 | 7,499,000 | 1,572,000 | -467,000 |
| Depreciation | 2,665,000 | 2,751,000 | 1,949,000 | 1,030,000 | 173,000 | 56,000 | 44,000 | 10,000 | 10,000 | 0 |
| Amortisation | 95,804,000 | 91,952,000 | 83,757,000 | 47,831,000 | 40,282,000 | 33,688,000 | 12,084,000 | 12,299,000 | 3,621,000 | 537,000 |
| Tax | -1,227,000 | -18,000 | -136,000 | 251,000 | -2,477,000 | -5,012,000 | -3,066,000 | -1,850,000 | -384,000 | 0 |
| Stock | -10,122,000 | 7,074,000 | 14,674,000 | 3,691,000 | 7,388,000 | -972,000 | 3,740,000 | 2,726,000 | 1,259,000 | 348,000 |
| Debtors | 30,697,000 | 7,036,000 | -39,988,000 | 74,647,000 | 5,286,000 | 9,933,000 | 6,019,000 | 4,257,000 | 1,267,000 | 2,303,000 |
| Creditors | 16,391,000 | 292,000 | -49,196,000 | 54,069,000 | 3,617,000 | -1,027,000 | 232,000 | 1,770,000 | 584,000 | 308,000 |
| Accruals and Deferred Income | 70,024,000 | -9,624,000 | 28,949,000 | 5,659,000 | 2,143,000 | 7,021,000 | -1,529,000 | 2,054,000 | 949,000 | 690,000 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | 208,200,000 | 75,737,000 | 105,995,000 | 41,201,000 | 49,992,000 | 54,222,000 | 15,277,000 | 14,799,000 | 3,826,000 | -1,583,000 |
| Investing Activities | ||||||||||
| capital expenditure | 0 | 0 | 0 | 0 | 0 | -17,635,000 | ||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | -202,000 | 202,000 | 0 | 0 | 0 |
| cash flow from investments | 0 | 202,000 | -202,000 | 0 | 0 | -17,635,000 | ||||
| Financing Activities | ||||||||||
| Bank loans | 0 | 0 | 0 | -29,352,000 | 12,779,000 | 16,573,000 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 33,243,000 | 0 | 0 | 0 | -376,000 | -307,000 | -55,404,000 | 4,314,000 | 31,680,000 | 20,093,000 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | -16,717,000 | 16,717,000 | -1,764,000 | 1,764,000 | 0 | 0 |
| Long term loans | 14,001,000 | -507,822,000 | 65,090,000 | 844,553,000 | -18,143,000 | 30,061,000 | 67,857,000 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | -265,000 | -7,000 | 53,000 | 4,238,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 106,463,000 | -10,809,000 | 7,367,000 | 20,121,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | ||||||||||
| interest | -48,193,000 | -4,405,000 | -22,177,000 | -14,235,000 | -8,677,000 | -8,332,000 | -3,744,000 | -3,402,000 | -881,000 | -192,000 |
| cash flow from financing | 105,038,000 | -525,334,000 | 48,269,000 | 823,651,000 | -31,134,000 | 53,265,000 | 7,093,000 | 2,676,000 | 30,799,000 | 19,901,000 |
| cash and cash equivalents | ||||||||||
| cash | -3,638,000 | 26,036,000 | 1,112,000 | 12,997,000 | 1,315,000 | -1,694,000 | -12,984,000 | 12,604,000 | 3,075,000 | 212,000 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | -3,638,000 | 26,036,000 | 1,112,000 | 12,997,000 | 1,315,000 | -1,694,000 | -12,984,000 | 12,604,000 | 3,075,000 | 212,000 |
P&L
March 2023turnover
352.8m
+44%
operating profit
45.1m
+904%
gross margin
67.5%
+9.27%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2023net assets
21.2m
-0.18%
total assets
803.4m
+0.42%
cash
39m
-0.09%
net assets
Total assets minus all liabilities
atnahs pharma uk limited company details
company number
08789556
Type
Private limited with Share Capital
industry
46460 - Wholesale of pharmaceutical goods
21100 - Manufacture of basic pharmaceutical products
incorporation date
November 2013
age
11
accounts
Group
ultimate parent company
previous names
atnahs uk holdings limited (April 2014)
incorporated
UK
address
sovereign house miles gray road, basildon, essex, SS14 3FR
last accounts submitted
March 2023
atnahs pharma uk limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 11 charges/mortgages relating to atnahs pharma uk limited. Currently there are 7 open charges and 4 have been satisfied in the past.
atnahs pharma uk limited Companies House Filings - See Documents
| date | description | view/download |
|---|
